Skip to main content

Table 3 Quality assessment of included randomized controlled trials

From: Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials

Trial Follow up duration Blinded Concealed allocation Intention to treat analysis Not stopped early for benefit <5 % Randomized Patients with Missing Outcome Data
Nidorf 2013 [14] 3 years (median) [minimum 2 years] Outcome assessors only Yes Yes Yes Yes (0 %, 0/532)
Raju 2012 [15] 32 days (median) Yes Yes Yes Yes No (7.3 %, 6/82)
O’Keefe 1992 [16] 5.5 months (mean) Yes n/r n/r Yes Unclear (unsuccessful PTCA patients excluded but randomized before PTCA)
Deftereos 2013 [7] 6 months (all) Yes n/r Yes Yes Yes (0 %, 0/222 [clinical outcomes])
Deftereos 2014 [17] 6 months (all) Yes n/r Yes Yes Yes (1.1 %, 3/279)
Finkelstein 2002 [23] 3 months (all) Yes n/r Yes Yes No (32 %, 52/163)
COPE 2005 (Imazio) [18] 20 months (mean) No n/r Yes n/r Yes (0 %)
ICAP 2013 (Imazio) [19] 18 months (all)/ 22 months (mean) Yes Yes Yes Yes Yes (0 %)
CORE 2005 (Imazio) [20] 18 months (all)/ 20 months (mean) No n/r Yes n/r Yes (0 %)
CORP 2011 (Imazio) [28] 18 months (all)/ 23 months (mean) Yes Yes Yes Yes Yes (0 %)
CORP-2 2014 (Imazio) [22] 18 months (all)/ 20 months (mean) Yes Yes Yes Yes Yes (0 %)
COPPS 2010/1 (Imazio) [24, 28] 19 months (mean) Yes Yes Yes Yes Yes (0 %)
COPPS-2 2014 (Imazio) [25] 3 months (median) Yes Yes Yes Yes Yes (0 %)
Sarzaeem 2014 [26] 7 days (mean) (hospital discharge) Yes n/r n/r Yes Unclear (excluded patients unable to tolerate enteral medications within 48 h post cardiac surgery)
Deftereos 2012/ 2014 [17, 27] 3 months (?all)/ 15 months (median) Yes n/r Yes Yes No (10 %, 24/230 [AFib recurrence]; 6.1 %, 14/230 [adverse events])
  1. Abbreviations: AFib atrial fibrillation, n/r not reported, PTCA percutaneous coronary angioplasty